News NetraMark Holdings Inc.

Stocks

AIAI

CA64119M1059

Software

Delayed Toronto S.E. 01:29:37 29/10/2026 am IST			5-day change	1st Jan Change
0.5800 ^CAD	+5.45%		-1.69%	-47.27%

10/09	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
01/09	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors	CI

All News

Mentions Relevance

08/10	NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright's AI-Based Drug Discovery and Development Conference	AQ
07/10	NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference	AQ
10/09	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
10/09	Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models	AQ
08/09	NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor	AQ
01/09	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors	CI
01/09	NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier	AQ
27/08	NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	AQ
20/08	NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High	AQ
14/08	NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
13/07	NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness	AQ
09/07	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data	MT
09/07	NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	CI
09/07	NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	AQ
29/06	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
29/06	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI
29/06	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	AQ
09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
25/05	Upcoming Meeting Dates - May 25, 2026	NE
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
15/05	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
15/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
08/05	NetraMark Announces Change To Board Of Directors	AQ
08/05	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026	CI
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE